Abstract | BACKGROUND: METHODS: We conducted a nonblinded, prospective intervention study. During 1 year, patients received a monthly intramuscular injection of 30 mg octreotide. Pretreatment and posttreatment tumor volumes were assessed by MRI, urinary catecholamine secretion was measured, and HNPGL-related signs and symptoms were recorded. RESULTS: In 1 of 4 included patients with HNPGL, a stabilization of tumor growth was observed after octreotide therapy. In 1 patient, octreotide therapy was discontinued before the end of the study because of potential side effects. No improvements in HNPGL-related signs and symptoms were observed. CONCLUSION:
|
Authors | Leonie T van Hulsteijn, Nicolette van Duinen, Berit M Verbist, Jeroen C Jansen, Agatha A van der Klaauw, Jan W A Smit, Eleonora P M Corssmit |
Journal | Head & neck
(Head Neck)
Vol. 35
Issue 12
Pg. E391-6
(Dec 2013)
ISSN: 1097-0347 [Electronic] United States |
PMID | 23606330
(Publication Type: Journal Article)
|
Copyright | Copyright © 2013 Wiley Periodicals, Inc. |
Chemical References |
- Antineoplastic Agents, Hormonal
- Catecholamines
- Contrast Media
- Succinate Dehydrogenase
- Octreotide
|
Topics |
- Adult
- Aged
- Antineoplastic Agents, Hormonal
(therapeutic use)
- Catecholamines
(urine)
- Contrast Media
- Female
- Head and Neck Neoplasms
(drug therapy, genetics, pathology)
- Humans
- Injections, Intramuscular
- Magnetic Resonance Angiography
- Magnetic Resonance Imaging
- Male
- Middle Aged
- Mutation
- Octreotide
(therapeutic use)
- Paraganglioma
(drug therapy, genetics, pathology)
- Prospective Studies
- Succinate Dehydrogenase
(genetics)
|